Tango Therapeutics reports Q3 basic EPS loss
Tango Therapeutics reported Q3 operating expenses of USD 78.116 million.
Story updates
12:11:32 PM UTC
SquawkNews
OverviewOutlookResult DriversCompany press release:Key DetailsReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automati…
12:23:23 PM UTC
SquawkNews
Tango Therapeutics reported a third-quarter 2026 net loss of $68.4 million, compared with net income of $15.9 million a year earlier, as operating expenses rose and collaboration revenue fell to zero. The company ended September with $977.5 million in cash, cash equivalents and marketable securitie…